Indrayani Biotech Limited has announced the approval of its audited financial results for the quarter and year ended March 31, 2026. The Board of Directors, in its meeting on August 17, 2026, reviewed and approved both standalone and consolidated financial statements, along with the auditors’ report. These results will be published in newspapers and are available on the company’s website.
Indrayani Biotech Board Approves Audited Financials
In a significant corporate development, the Board of Directors at Indrayani Biotech Limited convened on Monday, August 17, 2026, to review and approve the audited financial results for the fiscal year ended March 31, 2026. This approval encompasses both the standalone and consolidated financial statements, accompanied by the auditors’ report.
Key Financials and Dissemination
The meeting, which commenced at 03:45 P.M. and concluded at 04:30 P.M., confirmed the financial outcomes for the period. The company has made arrangements to publish these audited financial results in leading newspapers. Furthermore, the complete financial statements will be accessible on the company’s official website, indrayani.com, and on the BSE’s website, providing transparency to stakeholders. The scrip code for Indrayani Biotech Limited is 526445.
Auditor’s Report Highlights
The independent auditor’s report, issued by Venkatesh & Co, Chartered Accountants, indicates a qualified opinion on the consolidated financial results. The qualifications are based on certain uncertainties and limitations, including the inability to ascertain the consequential impact on the financial statements due to pending confirmations and reconciliations for loans, other current assets, and trade receivables. Additionally, the consolidation of accounts for certain subsidiaries was based on INDIAN GAAP rather than IND AS, and there were limitations in obtaining audit evidence for specific trade creditor balances from one subsidiary. The report also notes that the figures for the corresponding year ended March 31, 2026, as reported in these financial results, were approved by the Board but had not been subjected to audit/review.
Source: BSE
